Floatz logo

.GAMMA.-HYDROXYBUTYRATE SODIUM SALT

Chronic Fatigue Syndrome

University of Medicine and Dentistry of New JerseySmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Chronic Fatigue Syndrome cohort.

Asset / SponsorPhaseRating
NORAMITRIPTYLINE
Duke University
Phase 2B
Naltrexone
Brigham and Women's Hospital
Phase 2CCC
Pyridostigmine
Brigham and Women's Hospital
Phase 2CCC
AUTOLOGOUS LEUKOCYTES, 89ZR-OXINE LABELED
University of Alabama at Birmingham
Phase 1CC
CITALOPRAM
Vrije Universiteit Brussel
N/AD
Ribavirin
Aarhus University Hospital
N/AD

Same molecule, other indications

.GAMMA.-HYDROXYBUTYRATE SODIUM SALT is also rated in:

narcolepsyDormant
BB
Indicative ·
66 / 100
View asset →
REM sleep behavior disorderDormant
BB
Indicative ·
65 / 100
View asset →
Alzheimer diseaseDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →